Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Peginterferon Alfa-2a And Ribavirin For 16 Or 24 Weeks In Hcv Genotype 2 Or 3, Mitchell L. Shiffman, Fredy Suter, Bruce R. Bacon, David Nelson, Hugh Harley, Richard Sola, Stephen D. Shafran, Karl Barange, Amy Lin, Ash Soman, Stefan Zeuzem
Peginterferon Alfa-2a And Ribavirin For 16 Or 24 Weeks In Hcv Genotype 2 Or 3, Mitchell L. Shiffman, Fredy Suter, Bruce R. Bacon, David Nelson, Hugh Harley, Richard Sola, Stephen D. Shafran, Karl Barange, Amy Lin, Ash Soman, Stefan Zeuzem
VCU Health Publications
Background
Patients infected with hepatitis C virus (HCV) genotype 2 or 3 have sustained virologic response rates of approximately 80% after receiving treatment with peginterferon and ribavirin for 24 weeks. We conducted a large, randomized, multinational, noninferiority trial to determine whether similar efficacy could be achieved with only 16 weeks of treatment with peginterferon alfa-2a and ribavirin.
Methods
We randomly assigned 1469 patients with HCV genotype 2 or 3 to receive 180 μg of peginterferon alfa-2a weekly, plus 800 mg of ribavirin daily, for either 16 or 24 weeks. A sustained virologic response was defined as an undetectable serum HCV …
Eltrombopag For Thrombocytopenia In Patients With Cirrhosis Associated With Hepatitis C, John G. Mchutchison, Geoffrey Dusheiko, Mitchell L. Shiffman, Maribel Rodriguez-Torres, Samuel Sigal, Marc Bourliere, Thomas Berg, Stuart C. Gordon, Fiona M. Campbell, Dickens Theodore, Nicole Blackman, Julian Jenkins, Nezam H. Afdhal
Eltrombopag For Thrombocytopenia In Patients With Cirrhosis Associated With Hepatitis C, John G. Mchutchison, Geoffrey Dusheiko, Mitchell L. Shiffman, Maribel Rodriguez-Torres, Samuel Sigal, Marc Bourliere, Thomas Berg, Stuart C. Gordon, Fiona M. Campbell, Dickens Theodore, Nicole Blackman, Julian Jenkins, Nezam H. Afdhal
VCU Health Publications
Background
Eltrombopag is a new, orally active thrombopoietin-receptor agonist that stimulates thrombopoiesis. We evaluated its ability to increase platelet counts and facilitate treatment for hepatitis C virus (HCV) infection in patients with thrombocytopenia associated with HCV-related cirrhosis.
Methods
Seventy-four patients with HCV-related cirrhosis and platelet counts of 20,000 to less than 70,000 per cubic millimeter were randomly assigned to receive eltrombopag (30, 50, or 75 mg daily) or placebo daily for 4 weeks. The primary end point was a platelet count of 100,000 per cubic millimeter or more at week 4. Peginterferon and ribavirin could then be initiated, with continuation …